

WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: 107/22, Gali No-3 East Azad Nagar, Shahdara, New Delhi-110051

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Date: 14.11.2023

To,

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Ref: Scrip Code: 524661-- Welcure Drugs & Pharmaceuticals Ltd.

Subject: Un-audited Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

With reference to the above captioned subject, it is to inform you that following are the Un-audited Financial Results approved at the Board Meeting held today i.e. Tuesday, 14th November, 2023 at 03.00 P.M and concluded at 05.00 P.M at the registered office of the Company.

1. The Board considered and approved the Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2023.
2. The Board reviewed and took on record the Limited Review Report on the Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2023.

Please find enclosed therewith the copies of the following:

1. Un- Audited Financial Results of the Company for the quarter and half year ended 30th September, 2023.
2. Limited Review Report on the Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2023.

This is for your kind information and record please.

Thanking You

For Welcure Drugs & Pharmaceuticals Limited

Name: Vishal Mehra
DIN: 09717741
Designation: Managing Director
Address: 47, RadheyPuriExtn 2, Gali
No.4, Krishna Nagar, East Delhi,
Delhi-110051 Delhi-110051

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN: L24232DL1996PLC227773

Registered Office:107/22, Gali No-3 East Azad Nagar, Shahdara, New Delhi-110051

Statement of Un-Audited Financial Results for the Quarter Ended 30th September 2023

S. No.	Particulars	(Rs. in Lakhs)					
		Quarter Ended			Half Year Ended		Year Ended
		30.09.2023 Un-audited	30.06.2023 Un-audited	30.09.2022 Un-audited	30.09.2023 Un-audited	30.09.2022 Un-audited	31.03.2023 (Audited)
I	Income						
	a) Revenue from Operations	0.00	0.00	0.00	0.00	0.00	0.00
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
II	Other Income						
	a) Other Income	0.24	0.00	0.90	0.24	0.90	23.71
III	Total Income from operations (net)	0.24	0.00	0.90	0.24	0.90	23.71
IV	Expenses						
	Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work in progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee Benefit expenses	1.35	1.35	0.36	2.70	0.72	4.01
	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	Loss in Trading of shares	0.00	0.70	0.00	0.70	0.00	0.00
	Depreciation and amortisation expenses	1.00	0.00	0.00	1.00	0.00	0.32
	Other Expenses	7.39	1.27	1.17	8.66	6.46	9.21
	Total Expenses (IV)	9.74	3.32	1.53	13.06	7.18	13.54
V	Profit/(Loss) before exceptional items (I-IV)	-9.50	-3.32	-0.63	-12.83	-6.28	10.17
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/(Loss) before extraordinary items and tax (v-vi)	-9.50	-3.32	-0.63	-12.83	-6.28	10.17
VIII	extraordinary items	0.00	0.00	0.00		0.00	0.00
IX	Profit/(Loss) before tax (VII-VIII)	-9.50	-3.32	-0.63	-12.83	-6.28	10.17
X	Tax Expenses						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Profit/(Loss) for the period from continuing operations (IX - X)	-9.50	-3.32	-0.63	-12.83	-6.28	10.17
XII	Net Profit/(Loss) for the period from discontinuing operations (before tax)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Tax expenses of discontinued operations	0.00	0.00	0.00		0.00	0.00
XIV	Net Profit/(Loss) for the period from discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00	0.00
XV	Net Profit/(Loss) for the period (XI+XIV)	-9.50	-3.32	-0.63	-12.83	-6.28	10.17
XVI	Share of profit / (loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Share of profit / (loss) of minority	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates	-9.50	-3.32	-0.63	-12.83	-6.28	10.17
XIX	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
XX	Total Comprehensive Income for the period (XVIII-XIX)	-9.50	-3.32	-0.63	-12.83	-6.28	10.17
XXI	Paid up share capital (Face Value of Rs. 10/- per share)	1,343.91	1,343.91	1,343.91	1,343.91	1,343.91	1,343.91
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00
XXIII	Earning per Equity Share (for continuing operations):						
	(1) Basic	-0.007	-0.002	0.000	-0.010	-0.005	0.008
	(2) Diluted	-0.007	-0.002	0.000	-0.010	-0.005	0.008


Notes:-

1. The above Un-Audited results were reviewed by the Audit Committee and were approved by the Board of Directors of the company at its meeting held on 14th November, 2023.
2. Due to Loss, the Board of Directors have not declared any interim dividend for the fiscal year.
3. There were no investor complaints pending during the Quarter ended September 30, 2023
4. As the Company is mainly operating in one reportable business segment, hence the disclosure requirements of Indian Accounting Standard (Ind AS-108) "Operating Segment" is not applicable.
5. The Previous Quarter ended figures have been re-grouped/ re-arranged, whenever necessary.
6. There is no need to provide any reconciliation as required by the circular dated July 05, 2016, since there is no change in the figures due to transil from the previous Indian GAAP to Ind-AS.

For WELCURE DRUGS AND PHARMACEUTICALS LIMITED

Vishal Mehra
Managing Director
DIN: 09717741

Place :- Delhi
Date :- 14-11-2023



(Handwritten Signature)



WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN: L24232DL1996PLC227773

Registered Office: 107/22, Gali No-3 East Azad Nagar, Shahdara, New Delhi-110051

STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2023

S. No.	Particulars	(Rs. In Lakhs)	
		30th	31st March
A. ASSETS			
(1) Non-Current Assets			
(a)	Property, Plant and Equipment	4.68	5.68
(b)	Capital work-in-progress	-	-
(c)	Goodwill	-	-
(d)	Other Intangible assets	-	-
(e) Financial Assets			
(i)	Investments	1.92	16.50
(ii)	Loans	123.54	127.04
(iii)	Other Financial Assets	-	-
(f)	Other Non Current Assets	3.08	3.08
Total Non Current Assets		133.22	152.30
(2) Current Assets			
(a)	Inventories	-	-
(b) Financial Assets			
(i)	Loans	-	-
(ii)	Trade Receivables	-	-
(iii)	Cash and Cash Equivalents	3.97	0.12
(iv)	Short Term Loans and Advances	2.93	0.02
(c)	Other Current Assets	0.45	0.45
Total - Current Assets		7.35	0.59
TOTAL ASSETS		140.56	152.89
B. EQUITY AND LIABILITIES			
(1) Equity			
(a)	Share Capital	1,343.91	1,343.91
(b)	Other Equity	(1,205.21)	(1,192.38)
Total Equity		138.70	151.53
(2) Liabilities			
(I) Non Current Liabilities			
(a)	Financial Liabilities	-	-
(i)	Borrowings	-	-
(b)	Provisions	-	-
(c)	Deferred Tax Liabilities	-	-
(d)	Other Non Current Liabilities	-	-
Total Non Current Liabilities		-	-
(II) Current Liabilities			
(a) Financial Liabilities			
(i)	Borrowings	-	-
(ii)	Trade Payables	-	-
(iii)	Other Financial Liabilities	1.86	1.36
(b)	Other Current Liabilities	-	-
(c)	Provisions	-	-
(d)	Current Tax Liabilities (Net)	-	-
Total Current Liabilities		1.86	1.36
TOTAL EQUITY AND LIABILITIES		140.56	152.89

For and on behalf of the Board
For Welcure Drugs and Pharmaceuticals LtdShal Mehra
Director
DIN: 09717741

Place :- Delhi

Date :- 14-11-2023

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN: L24232DL1996PLC227773

Registered Office: 107/22, Gali No-3 East Azad Nagar, Shahdara, New Delhi-110051

STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 30.09.2023

(Rs. In Lakhs)

S. No.	Particulars	30th Sep 2023	31st March 2023
A	Cash Flows from Operating Activities:		
	Net profit / (loss) before taxation	(12.83)	10.17
	Adjustments for :		
	Depreciation	1.00	0.00
	Operating Profit before Working Capital Changes	(11.83)	10.17
	(Increase) / Decrease in Other Assets	(0.00)	(0.45)
	(Increase) / Decrease in Other Financial Liabilities - Current	2.91	(0.02)
	(Increase) / Decrease in Other Current Liabilities	0.50	0.98
	Cash Generated from Operations	(14.23)	10.69
	Less: Tax paid	0.00	0.00
	Net cash flow from / (used) in operating activities (A)	(14.23)	10.69
B	Cash Flows from Investing Activities:		
	Net Cash from Investment activity	(14.57)	132.05
	Net Cash From Investing (B)	(14.57)	132.05
C	Cash flow from Financing Activities:		
	Net Cash from Financiiing Activities	(3.50)	(149.22)
	Net Cash Used In Financing Activities (C)	(3.50)	(149.22)
	Net Increase in Cash and Cash Equivalents (A+B+C)	3.85	(6.48)
	Cash and Cash Equivalents at beginning of Period	0.12	6.60
	Cash and Cash Equivalents at end of Period	3.97	0.12
		3.85	(6.48)

For and on behalf of the Board
For Welcure Drugs and Pharmaceuticals Ltd
Vishal Mehra
Managing Director
DIN: 09717741Place :- Delhi
Date :- 14-11-2023

BMGS & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of WELCURE DRUGS AND PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI

(Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO,

The Board of Directors

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

Opinion

1. We have reviewed the accompanying Statement of Unaudited Financial Results of WELCURE DRUGS AND PHARMACEUTICALS LIMITED ("the Company") for the Quarter and Half Year ended September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including relevant circulars issued by the Securities and Exchange Board of India.

2. This Statement, which is responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related interim condensed financial statements which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under the Section 133 of the Companies Act 2013("the Act") and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the Securities and Exchange Board of India. Our responsibility is to issue a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

HeadOffice: B-9,SardarNagar,GTRoad,Delhi-110009

Delhi|Gurugram|Noida

Tele:+911127120796

Mobile:+91987110365

Email:mail@bmgs.in

Web:www.bmgs.in



We also performed procedures in accordance with the SEBI circular CIR/CFD/CMD1/44/2019 DATED 29 March 2019 issued by SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **BMGS & Associates**
Chartered Accountants
Firm Reg. No 026886N



Vaibhav Bajaj, FCA
M. No. 520512
Partner
UDIN: 23520512BGSPZZ2499

Place: New Delhi
Date: 14/11/2023